Adah S Zhang1,2, Quinn T Ostrom3,4, Carol Kruchko4, Lisa Rogers3,5, David M Peereboom3,6, Jill S Barnholtz-Sloan3,4. 1. Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 2. Department of Statistical Sciences, Sandia National Laboratories, Albuquerque, New Mexico, USA. 3. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 4. Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA. 5. Brain Tumor and Neuro-Oncology Center, University Hospitals Case Medical Center, Cleveland, Ohio, USA. 6. Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
Background: Complete prevalence proportions illustrate the burden of disease in a population. This study estimates the 2010 complete prevalence of malignant primary brain tumors overall and by Central Brain Tumor Registry of the United States (CBTRUS) histology groups, and compares the brain tumor prevalence estimates to the complete prevalence of other common cancers as determined by the Surveillance, Epidemiology, and End Results Program (SEER) by age at prevalence (2010): children (0-14 y), adolescent and young adult (AYA) (15-39 y), and adult (40+ y). Methods: Complete prevalence proportions were estimated using a novel regression method extended from the Completeness Index Method, which combines survival and incidence data from multiple sources. In this study, two datasets, CBTRUS and SEER, were used to calculate complete prevalence estimates of interest. Results: Complete prevalence for malignant primary brain tumors was 47.59/100000 population (22.31, 48.49, and 57.75/100000 for child, AYA, and adult populations). The most prevalent cancers by age were childhood leukemia (36.65/100000), AYA melanoma of the skin (66.21/100000), and adult female breast (1949.00/100000). The most prevalent CBTRUS histologies in children and AYA were pilocytic astrocytoma (6.82/100000, 5.92/100000), and glioblastoma (12.76/100000) in adults. Conclusions: The relative impact of malignant primary brain tumors is higher among children than any other age group; it emerges as the second most prevalent cancer among children. Complete prevalence estimates for primary malignant brain tumors fills a gap in overall cancer knowledge, which provides critical information toward public health and health care planning, including treatment, decision making, funding, and advocacy programs.
Background: Complete prevalence proportions illustrate the burden of disease in a population. This study estimates the 2010 complete prevalence of malignant primary brain tumors overall and by Central Brain Tumor Registry of the United States (CBTRUS) histology groups, and compares the brain tumor prevalence estimates to the complete prevalence of other common cancers as determined by the Surveillance, Epidemiology, and End Results Program (SEER) by age at prevalence (2010): children (0-14 y), adolescent and young adult (AYA) (15-39 y), and adult (40+ y). Methods: Complete prevalence proportions were estimated using a novel regression method extended from the Completeness Index Method, which combines survival and incidence data from multiple sources. In this study, two datasets, CBTRUS and SEER, were used to calculate complete prevalence estimates of interest. Results: Complete prevalence for malignant primary brain tumors was 47.59/100000 population (22.31, 48.49, and 57.75/100000 for child, AYA, and adult populations). The most prevalent cancers by age were childhood leukemia (36.65/100000), AYA melanoma of the skin (66.21/100000), and adult female breast (1949.00/100000). The most prevalent CBTRUS histologies in children and AYA were pilocytic astrocytoma (6.82/100000, 5.92/100000), and glioblastoma (12.76/100000) in adults. Conclusions: The relative impact of malignant primary brain tumors is higher among children than any other age group; it emerges as the second most prevalent cancer among children. Complete prevalence estimates for primary malignant brain tumors fills a gap in overall cancer knowledge, which provides critical information toward public health and health care planning, including treatment, decision making, funding, and advocacy programs.
Authors: Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers Journal: Neuro Oncol Date: 2012-03-09 Impact factor: 12.300
Authors: Quinn T Ostrom; Haley Gittleman; Peter M de Blank; Jonathan L Finlay; James G Gurney; Roberta McKean-Cowdin; Duncan S Stearns; Johannes E Wolff; Max Liu; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2016-01 Impact factor: 12.300
Authors: Quinn T Ostrom; Haley Gittleman; Carol Kruchko; David N Louis; Daniel J Brat; Mark R Gilbert; Valentina I Petkov; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2016-07-14 Impact factor: 4.130
Authors: Haley R Gittleman; Quinn T Ostrom; Chaturia D Rouse; Jacqueline A Dowling; Peter M de Blank; Carol A Kruchko; J Bradley Elder; Steven S Rosenfeld; Warren R Selman; Andrew E Sloan; Jill S Barnholtz-Sloan Journal: Cancer Date: 2014-08-25 Impact factor: 6.860
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Haley Gittleman; Alexander Boscia; Quinn T Ostrom; Gabrielle Truitt; Yi Fritz; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2018-11-09 Impact factor: 12.300
Authors: Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander Journal: Neuro Oncol Date: 2018-07-05 Impact factor: 12.300
Authors: Gabrielle Truitt; Haley Gittleman; Rebecca Leece; Quinn T Ostrom; Carol Kruchko; Terri S Armstrong; Mark R Gilbert; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2019-06-17 Impact factor: 4.130
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: Viveka Nand Yadav; David Altshuler; Padma Kadiyala; Daniel Zamler; Andrea Comba; Henry Appelman; Patrick Dunn; Carl Koschmann; Maria G Castro; Pedro R Löwenstein Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: David B Altshuler; Lin Wang; Lili Zhao; Zachary Miklja; Joey Linzey; Amanda Brezzell; Sofia Kakaizada; Saritha Krishna; Daniel A Orringer; Emily M Briceño; Nicolette Gabel; Shawn L Hervey-Jumper Journal: Neurooncol Pract Date: 2019-04-10
Authors: Nirav Patil; Michael E Kelly; Debra Nana Yeboa; Robin A Buerki; Gino Cioffi; Sweta Balaji; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300